VPD-737 for Treatment of Chronic Pruritus
A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus
  • Phase

    Phase 2
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    serlopitant ...
  • Study Participants

A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments
The sensation of itch is transmitted to the brain through the nervous system Several chemicals are involved in transmitting this signal This trial of VPD 737 is intended to treat this condition by blocking one of the chemicals involved in the transmission of the itch signal This is an oral drug administered once daily It has been used in other trials and has shown to be safe at the doses used in this trial The trial will involve once daily pills for 6 weeks. Subject will be asked to fill out questionnaires both electronically and on paper during the study period Patients will also be monitored for safety and will have blood taken for testing and several points during the trial Overall participation will last about 12 weeks
Study Started
Oct 15
Primary Completion
Dec 02
Study Completion
Dec 02
Last Update
May 13

Drug VPD-737

NK1 Receptor Antagonist

  • Other names: Serlopitant

Drug Placebo

0.25 mg VPD-737 Experimental

0.25 mg of VPD-737 daily by mouth for 42 days

1 mg VPD-737 Experimental

1 mg VPD-737 taken daily by mouth for 42 days

5 mg VPD-737 Experimental

5 mg tablets of VPD-737 to be taken daily by mouth for 42 days

Placebo Placebo Comparator

placebo tablets to be taken daily by mouth for 42 days


Inclusion Criteria:

Clinical diagnosis of chronic pruritus and unresponsive to current therapies

Exclusion Criteria:

Have chronic liver or renal disease
No Results Posted